FOR IMMEDIATE RELEASE FEBRUARY 8, 2012
VANCOUVER, CANADA—QLT Inc. (NASDAQ: QLTI; TSX: QLT) will be presenting at the Leerink Swann 2012 Global Healthcare Conference in New York on Wednesday, February 15, 2012, at 4:00 p.m. Eastern Time. Bob Butchofsky, QLT's President and Chief Executive Officer, will be discussing the Company's two primary development programs: (i) a synthetic retinoid, QLT091001, for the treatment of Leber Congenital Amaurosis and Retinitis Pigmentosa; and (ii) the Company's Punctal Plug Delivery System for the treatment of glaucoma.
The live audio webcast of QLT’s presentation can be accessed through the Company’s web site at www.qltinc.com.
About QLT
QLT is an ocular-focused company dedicated to the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. We are focused on developing our synthetic retinoid program for the treatment of certain inherited retinal diseases, developing our proprietary punctal plug delivery system, as well as U.S. marketing of the commercial product Visudyne® (which we co-developed with Novartis) for the treatment of wet age-related macular degeneration.
QLT’s head office is based in Vancouver, Canada and the Company is publicly traded on NASDAQ (symbol: QLTI) and the Toronto Stock Exchange (symbol: QLT). For more information about the Company’s products and developments, please visit our web site at www.qltinc.com.
QLT Inc. Media Contact:
Karen Peterson
Corporate Communications Specialist
Telephone: 604-707-7000 or 1-877-764-3131
kpeterson@qltinc.com
QLT Inc. Investor Relations Contact:
David Climie
VP, Investor Relations
Telephone: 604-707-7573
dclimie@qltinc.com
Visudyne® is a registered trademark of Novartis AG.
|
